Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence...

Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design
Excellence Award
Award Honors Product Innovation, Design and Engineering Achievement, End-user
Benefit, and Cost-effectiveness in Manufacturing and Healthcare Delivery

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the
inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion
pulse oximetry, has received the 2009 Silver Medical Design Excellence Award
in the general hospital devices and therapeutic products category for the
Masimo Rad-87 Pulse CO-Oximeter. The award recognizes Rad-87's excellence in
medical technology engineering and design as an intuitive bedside patient
monitor that helps improve clinical efficiency and keep patients safe when a
clinician can't be at the bedside.

The Masimo Rad-87 features the breakthrough noninvasive blood constituent
monitoring capabilities of Masimo Rainbow SET((R)) Pulse CO-Oximetry for
continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI
(fluid responsiveness), perfusion index, and measure through motion pulse
oximetry with upgradability to acoustic respiration rate monitoring. Its
built-in 802.11a/b/g radio allows wireless communication with the Masimo
Patient SafetyNet(TM) remote monitoring and clinician notification system to
provide patients with an enhanced level of safety on general care floors.
Designed for ease-of-use, the Rad-87 allows the features clinicians need most
often to be accessed with a single touch. And, as the first Masimo Rainbow SET
device with a bright white LED-based display, its high contrast visual display
allows measurements to be clearly seen from across the room, while an
innovative new device profile feature lets clinical settings be customized and
color-coded for a particular care area.

Masimo Founder and CEO, Joe E. Kiani, stated, "It is an honor to receive our
third Medical Design Excellence Award for product design and engineering
innovations that improve healthcare delivery and advance medical practices. We
received the Gold Medical Design Excellence Award in 2006 for the Masimo
Rad-57 Pulse CO-Oximeter and in 2001 for the Masimo Radical Signal Extraction
pulse oximeter."

The Medical Design Excellence Awards (MDEA) competition is the only awards
program that exclusively recognizes advances in the design of medical products
and the achievements of medical device manufacturers responsible for the
groundbreaking innovations that are changing the face of healthcare. 2009 MDEA
winners were announced and honored at the June 10th ceremony during the
Medical Design & Manufacturing (MD&M) East Conference and Exposition in New
York. For more information about the Medical Design Excellence
Awards--including details about the winning products--visit www.MDEAwards.com.

About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO((R))),
methemoglobin (SpMet((R))), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements
This press release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, in connection with the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on current expectations
about future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our control
and could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various risk
factors, including, but not limited to: risks related to our belief that the
features, function and design of the Masimo Rad-87 Pulse CO-Oximeter will
enable clinicians to detect and treat life-threatening conditions earlier,
improve patient outcomes, increase clinical efficiency gains, and reduce the
cost of care for patients, risks related to our belief that Masimo Rainbow SET
Pulse CO-Oximetry technology will provide a sufficient level of sensitivity
and specificity to facilitate the noninvasive, continuous measurement of
multiple blood constituents, fluid assessment and physiological parameters,
risks related to our assumption that the combination of Masimo Rad-87 and
Masimo Patient SafetyNet will help clinicians keep patients safe on general
care floors, as well as other factors discussed in the "Risk Factors" section
of our Quarterly Report on Form 10-Q for the fiscal quarter year ended April
4, 2009, filed with the Securities and Exchange Commission ("SEC") on May 6,
2009, which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Contact:
Dana Banks
Masimo Corporation
949-297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation.

SOURCE Masimo

Dana Banks of Masimo Corporation, +1-949-297-7348